Fig. 2

rs2104286 in IL2RA in relation to achieving DMARD-free sustained remission in RA patients of the ESPOIR cohort and in meta-analysis of the Leiden EAC and ESPOIR cohorts. a In 622 RA patients of the ESPOIR cohort, the HR per minor C allele for achieving remission was 1.31 (95 % CI = 0.90–1.90, p = 0.16). The analysis was adjusted for age and gender. The minor allele frequency in the ESPOIR cohort was 23.2 %. b Results of the Leiden EAC and ESPOIR cohorts were combined in an inverse variance weighted meta-analysis: I ² = 0.0 %, p = 0.53, fixed-effect p = 1.01 × 10⁻³, random-effects p = 1.01 × 10⁻³. CI confidence interval, DMARD disease-modifying antirheumatic drug, EAC early arthritis clinic, ESPOIR Evaluation et Suivi de POlyarthrites Indifférenciées Récentes, HR hazard ratio, IL2RA interleukin-2 receptor alpha